Jyoti S. Mayadev, MD, Details Durvalumab’s Impact on Treatment Exposure/Delivery in Combination With CRT in Locally Advanced Cervical Cancer


Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, CancerNetwork® spoke with Jyoti S. Mayadev, MD, about how durvalumab (Infinzi) in combination with chemoradiotherapy (CRT) affected treatment exposure and delivery in patients with high-risk locally advanced cervical cancer based on data from the phase 3 CALLA trial (NCT03830866).

Mayadev, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine, detailed the regimen’s promising relative dose intensity and delivery data.


In terms of the treatment exposure and delivery, durvalumab had no impact in terms of the ability to deliver timely and safe radiation. The durvalumab/placebo relative dose intensity was excellent across the board in roughly 96% of the durvalumab/chemoradiation arm and 95% of the placebo/CRT arm. Patients received chemoradiation 99% to 100% of the time. In terms of the number of cycles of concurrent chemotherapy and cisplatin in patients, more than 86% to 88% of patients received more than 5 cycles of chemotherapy. The radiation itself was delivered per protocol in terms of the external beam radiation in [approximately] 96% of the time in the durvalumab arm and 98% in the placebo arm. And brachytherapy, most importantly, was delivered in [about] 95% of the entire population, with 94% being per protocol. These are very high numbers in terms of the quality that we see on the CALLA clinical trial.


Mayadev JS, Rong, Y, Toita T, et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting; October 23-26, 2022; San Antonio, TX; LBA 03. Accessed October 27, 2022.

Related Videos
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Related Content